Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Greillier

Showing results (71-80 of 153) with videos related to

Pageof 16
Sort By:
Clinical Lung Cancer|November 17, 2018
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung CancerMathieu Grangeon, Pascale Tomasini, Solene Chaleat, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2014
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validationBaktiar Hasan, Laurent Greillier, Athanasios Pallis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 4, 2021
Impact of care pathway for nursing home residents treated for cancer: ONCO-EHPAD studyAnne-Laure Couderc, Julie Berbis, Géraldine Delalande, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2021
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trialArmelle Lavole, Julien Mazieres, Sophie Schneider, et al.
Journal of Translational Medicine|September 19, 2023
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancerAlice Mogenet, Pascal Finetti, Emilie Denicolai, et al.
Journal of Geriatric Oncology|May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 studySébastien Gendarme, Sonia Zebachi, Romain Corre, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2022
Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancerFabrice Barlesi, Laure Deyme, Diane-Charlotte Imbs, et al.
Journal for Immunotherapy of Cancer|May 25, 2023
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumorsClémence Demerlé, Laurent Gorvel, Marielle Mello, et al.
JTO Clinical and Research Reports|September 30, 2021
Development and Validation of a Simplified Prognostic Score in SCLCElodie Negre, Amandine Coffy, Alexandra Langlais, et al.
The European Respiratory Journal|May 24, 2020
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trialArmelle Lavole, Laurent Greillier, Julien Mazières, et al.
Pageof 16

Showing results (71-80 of 153) with videos related to

Sort By:
Pageof 16
Clinical Lung Cancer|November 17, 2018
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung CancerMathieu Grangeon, Pascale Tomasini, Solene Chaleat, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2014
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validationBaktiar Hasan, Laurent Greillier, Athanasios Pallis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 4, 2021
Impact of care pathway for nursing home residents treated for cancer: ONCO-EHPAD studyAnne-Laure Couderc, Julie Berbis, Géraldine Delalande, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2021
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trialArmelle Lavole, Julien Mazieres, Sophie Schneider, et al.
Journal of Translational Medicine|September 19, 2023
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancerAlice Mogenet, Pascal Finetti, Emilie Denicolai, et al.
Journal of Geriatric Oncology|May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 studySébastien Gendarme, Sonia Zebachi, Romain Corre, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2022
Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancerFabrice Barlesi, Laure Deyme, Diane-Charlotte Imbs, et al.
Journal for Immunotherapy of Cancer|May 25, 2023
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumorsClémence Demerlé, Laurent Gorvel, Marielle Mello, et al.
JTO Clinical and Research Reports|September 30, 2021
Development and Validation of a Simplified Prognostic Score in SCLCElodie Negre, Amandine Coffy, Alexandra Langlais, et al.
The European Respiratory Journal|May 24, 2020
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trialArmelle Lavole, Laurent Greillier, Julien Mazières, et al.
Pageof 16